However, 17 participants had the same CH variants identified at both the Acute and Follow-up time points (between 80 and 115 weeks after ART initiation), and 9 (52.9%) of these patients had severe IRIS with or without HLH, with 6 (35.3%) individuals requiring prolonged immunosuppression for over 6 months. The gene discussed is C4B; the disease is hemophagocytic syndrome.